Food And Drug Administration-Meningococcal Disease-Bacterial Meningitis-Glaxosmithkline Plc

U.S. approves Glaxo meningitis vaccine for children

A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company results

WASHINGTON (Reuters) - U.S. regulators on Thursday approved a new children's vaccine from GlaxoSmithKline PLC that targets two common causes of bacterial meningitis, which can be fatal. The U.S. Food and Drug Administration said the vaccine, MenHibrix, is meant for children aged six weeks to 18 months and combines vaccines for meningococcal disease and Hib disease. The diseases are common causes of the infection. The FDA had rejected MenHibrix twice before, in 2010 and 2011, but GlaxoSmithKline said it had resolved regulators' questions about the vaccine's potency and efficacy. ... read more..

source:http://yhoo.it/MW5qWP